References
- Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
- Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022-4
- Sumelahti ML, Tienari PJ, Wikstrom J, et al. Increasing prevalence of multiple sclerosis in Finland. Acta Neurol Scand 2001;103:153-8
- Krokki O, Bloigu R, Reunanen M, et al. Increasing incidence of multiple sclerosis in women in Northern Finland. Mult Scler 2011;17:133-8
- Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
- Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012;18:7-15
- Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-25
- Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ 2013;16:939-50
- Karabudak R, Karampampa K, Caliskan Z, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey. J Med Econ 2015;18:69-75
- Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-85
- Svendsen B, Myhr KM, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ 2012;13:81-91
- Ellen N, Corbett J. International variation in drug usage: an exploratory analysis of the “causes” of variation. Santa Monica, CA: RAND Corporation, 2014. http://www.rand.org/pubs/research_reports/RR899. Accessed July 7, 2015
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006;7(2 Suppl):S5-13
- Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580-3
- EuroQoL Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
- Dolan P, Gudex C, Kind P, et al. A social tariff for the UK: results from a UK population survey. University of York: Centre for Health Economics, 1995
- Statistics Finland, Helsinki, Finland, 2014. http://www.tilastokeskus.fi/. Accessed June 10, 2014
- Kapiainen S, Vaisanen A, Haula T. Terveyden- ja sosilaalihuollon yksikkökustannukset Suomessa vuonna 2011. Helsinki, Finland: Terveyden ja hyvinvoinnin laitos, 2014
- Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol 2005;12(1 Suppl)1:63-7
- Confavreux C, Compston A. Chapter 4 - The natural history of multiple sclerosis. In: Compston A, Confavreux C, Lassmann H, et al., eds. McAlpine's Multiple Sclerosis, 4th ed. Edinburgh: Churchill Livingstone, 2006. p 183-272
- Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012;11:467-76
- Sarasoja T, Wikstrom J, Paltamaa J, et al. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. Acta Neurol Scand 2004;110:331-6
- Paltamaa J, Sarasoja T, Wikstrom J, et al. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med 2006;38:339-45
- Paz Soldan MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology 2015;84:81-8